comparemela.com

Latest Breaking News On - Jeito capital - Page 9 : comparemela.com

Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for

Proceeds will fund:- Clinical programs ALE.F02 and ALE.C04 – two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors- The platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodiesBASEL, Switzerland (BUSINESS WIRE) Alentis Therapeutics (“Alentis”).

Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1

Alentis Therapeutics ("Alentis"), the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, Alentis announced $105 million in Series C financing. The funding.

MIL-OSI: Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

MIL-OSI: Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.